吸入制剂用于肺部感染性疾病的研究进展  

Research Progress of Inhalation Preparations for Pulmonary Infectious Diseases

作　　者：郭俊彦 吴闻哲[1] 王健[1] GUO Junyan;WU Wenzhe;WANG Jian(National Advanced Medical Engineering Research Center,China State Institute of Pharmaceutical Industry,Shanghai 201203)

机构地区：[1]中国医药工业研究总院医药先进制造国家工程研究中心,上海201203

出　　处：《中国医药工业杂志》2023年第7期993-1001,共9页Chinese Journal of Pharmaceuticals

摘　　要：近年来,肺部感染性疾病对人类的健康造成了严重威胁。相较于传统的口服和注射给药途径,吸入给药被越来越多地用于治疗肺部感染性疾病。该途径可靶向递送药物至感染部位,具有提高肺部生物利用度、减少全身不良反应和耐药性的优势,因而受到广泛关注。该文概述了用于肺部感染性疾病治疗的吸入制剂的研究进展,以期为肺部吸入用抗感染药物的研发提供参考。In recent years,pulmonary infectious diseases have posed a serious threat to human health.Compared with the traditional oral and injection administration routes,inhalation administration is increasingly used to treat pulmonary infectious diseases.This route can achieve targeted delivery of drugs to the infected sites,and has the advantages of improving the pulmonary bioavailability,reducing systemic adverse reactions and drug resistance,and therefore has gained widely concern.This paper summarizes the research progress of inhalation preparations for treatment of pulmonary infectious diseases,with a view to providing references for the research and development of anti-infective drugs for pulmonary inhalation.

关 键 词：吸入制剂 肺部感染性疾病 吸入疫苗 吸入装置 

分 类 号：R944.9[医药卫生—药剂学]